Latest Insider Transactions at Igm Biosciences, Inc. (IGMS)
This section provides a real-time view of insider transactions for Igm Biosciences, Inc. (IGMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IGM Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IGM Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2022
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+50.0%
|
-
|
|
Sep 30
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
374
+9.93%
|
-
|
|
Sep 29
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
5,821
+14.15%
|
$110,599
$19.62 P/Share
|
|
Sep 28
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
6,172
+17.31%
|
$123,440
$20.97 P/Share
|
|
Sep 27
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
507
+2.13%
|
$9,633
$19.99 P/Share
|
|
Sep 08
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-10.58%
|
$190,000
$19.96 P/Share
|
|
Sep 08
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$0
$0.93 P/Share
|
|
Sep 07
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-20.21%
|
$190,000
$19.04 P/Share
|
|
Sep 07
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$0
$0.93 P/Share
|
|
Sep 06
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-11.24%
|
$95,000
$19.06 P/Share
|
|
Sep 06
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.1%
|
$0
$0.93 P/Share
|
|
Aug 22
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,300
-13.76%
|
$126,000
$20.71 P/Share
|
|
Aug 22
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,300
+12.09%
|
$0
$0.93 P/Share
|
|
Aug 19
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,700
-18.05%
|
$191,400
$22.82 P/Share
|
|
Aug 19
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,700
+15.29%
|
$0
$0.93 P/Share
|
|
Aug 18
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-20.21%
|
$220,000
$22.54 P/Share
|
|
Aug 18
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$0
$0.93 P/Share
|
|
Jul 18
2022
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
533
+2.28%
|
-
|
|
Jul 18
2022
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
533
-100.0%
|
-
|
|
Jun 30
2022
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
230
+0.31%
|
-
|
|
Jun 30
2022
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
346
+0.92%
|
-
|
|
Jun 30
2022
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+50.0%
|
-
|
|
Jun 30
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
230
+11.97%
|
-
|
|
Jun 30
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
374
+11.02%
|
-
|
|
Jun 30
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
230
+0.01%
|
-
|
|
May 26
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
950
-2.74%
|
$16,150
$17.1 P/Share
|
|
May 24
2022
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,362
-5.95%
|
$23,154
$17.1 P/Share
|
|
May 24
2022
|
George Gauthier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,340
-5.04%
|
$22,780
$17.1 P/Share
|
|
May 24
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
939
-2.32%
|
$15,963
$17.1 P/Share
|
|
May 24
2022
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,362
-3.85%
|
$23,154
$17.1 P/Share
|
|
May 24
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
938
-2.48%
|
$15,946
$17.1 P/Share
|
|
May 20
2022
|
Jakob Haldor Topsoe |
BUY
Open market or private purchase
|
Direct |
1,481
+1.98%
|
$23,696
$16.0 P/Share
|
|
May 13
2022
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
413
+1.77%
|
$4,956
$12.38 P/Share
|
|
May 13
2022
|
George Gauthier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
413
+1.53%
|
$4,956
$12.38 P/Share
|
|
May 13
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
413
+1.01%
|
$4,956
$12.38 P/Share
|
|
May 13
2022
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
414
+1.16%
|
$4,968
$12.38 P/Share
|
|
May 13
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
391
+1.12%
|
$4,692
$12.38 P/Share
|
|
May 13
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
825
+2.14%
|
$9,900
$12.38 P/Share
|
|
May 13
2022
|
Christina Teng Topsoe |
BUY
Open market or private purchase
|
Indirect |
4,510
+39.88%
|
$63,140
$14.99 P/Share
|
|
May 13
2022
|
Jakob Haldor Topsoe |
BUY
Open market or private purchase
|
Direct |
7,850
+9.83%
|
$109,900
$14.86 P/Share
|
|
May 12
2022
|
Christina Teng Topsoe |
BUY
Open market or private purchase
|
Indirect |
2,290
+50.0%
|
$32,060
$14.08 P/Share
|
|
May 12
2022
|
Jakob Haldor Topsoe |
BUY
Open market or private purchase
|
Direct |
8,254
+11.4%
|
$115,556
$14.17 P/Share
|
|
Apr 08
2022
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
533
+2.34%
|
-
|
|
Apr 08
2022
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
533
-100.0%
|
-
|
|
Apr 06
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-5.88%
|
$62,500
$25.0 P/Share
|
|
Apr 06
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+5.55%
|
$0
$0.93 P/Share
|
|
Apr 01
2022
|
M Kathleen Behrens |
BUY
Open market or private purchase
|
Indirect |
60,869
+22.24%
|
$1,399,987
$23.0 P/Share
|
|
Apr 01
2022
|
Michael D Loberg Director |
BUY
Open market or private purchase
|
Indirect |
21,739
+50.0%
|
$499,997
$23.0 P/Share
|
|
Mar 31
2022
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
374
+12.38%
|
-
|
|
Mar 31
2022
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+50.0%
|
-
|